![Medicine / Exenatide / Incretin / Glucagon-like peptide-1 analog / Anti-diabetic medication / Glucagon-like peptide-1 / European Medicines Agency / Sulfonylurea / Insulin resistance / Anti-diabetic drugs / Endocrine system / Gastroenterology Medicine / Exenatide / Incretin / Glucagon-like peptide-1 analog / Anti-diabetic medication / Glucagon-like peptide-1 / European Medicines Agency / Sulfonylurea / Insulin resistance / Anti-diabetic drugs / Endocrine system / Gastroenterology](https://www.pdfsearch.io/img/8b20b7424f716784bd9638f7d5195257.jpg)
| Document Date: 2013-07-21 06:16:23 Open Document File Size: 1,06 MBShare Result on Facebook
City London / / Company AMP / Eli Lilly Nederland B.V. / / Country United States / United Kingdom / / / Facility Canary Wharf / / IndustryTerm pharmaceutical and biological aspects / pharmaceutical development / drug product / medicinal product / downstream processing / manufacturing sites / sterile product / aseptic manufacturing process / rubber / chemical / chemical structure / medicinal products / manufacturing processes / closed manufacturing system / manufacturing process / / MedicalCondition insulin resistance / chronic widespread disease / sterility / diabetes / transmittable spongiform encephalitis / diabetes mellitus / type 2 diabetes mellitus / / MedicalTreatment oral therapies / / Organization European Medicines Agency / European Commission / European Union / E-mail info@ema.europa.eu Website www.ema.europa.eu An / CHMP / / Person Ion Chromatography / Pieter de Graeff / / / Product Byetta / sodium chloride / glucagon / glycine / / Technology Pharmacokinetics / antibodies / Gas Chromatography / Pharmacodynamics / recombinant DNA technology / / URL www.ema.europa.eu / /
SocialTag |